22nd Century Group logo
22nd Century Group XXII
$ 0.38 -17.39%
report update icon

Quarterly report 2026-Q3
added 11-16-2026

22nd Century Group Market Cap | XXII

As of November 19, 2026 22nd Century Group has a market cap of $ 69.9 K


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap 22nd Century Group

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
541 K 1.64 K 1.14 K 11.4 M 483 M 347 M 124 M 290 M 355 M 73.5 M 85.2 M 70.2 M 115 M 26.2 M 14.5 M - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
483 M 1.14 K 133 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
Seagen Seagen
SGEN
26.3 B - - $ 42.2 B usaUSA
Baudax Bio Baudax Bio
BXRX
779 K - 0.59 % $ 63 K usaUSA
ChemoCentryx ChemoCentryx
CCXI
1.88 M - - $ 3.74 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
423 M - - $ 789 M usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
52.7 M - 7.23 % $ 2.72 M usaUSA
Spectrum Pharmaceuticals Spectrum Pharmaceuticals
SPPI
123 M - - $ 189 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
24 B $ 0.34 -2.11 % $ 4.19 B israelIsrael
Berkeley Lights Berkeley Lights
BLI
117 M - -7.31 % $ 87 M usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
2.01 B $ 26.71 1.14 % $ 1.58 B usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
73.7 M - -3.69 % $ 12.4 M usaUSA
VBI Vaccines VBI Vaccines
VBIV
9.65 M - -50.87 % $ 1.09 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
551 M - - $ 1.2 B usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
102 M - - $ 123 M usaUSA
IVERIC bio IVERIC bio
ISEE
2.97 B - - $ 5.51 B usaUSA
ObsEva SA ObsEva SA
OBSV
156 M - -15.52 % $ 10.5 M schweizSchweiz
Monopar Therapeutics Monopar Therapeutics
MNPR
401 M $ 70.91 -0.21 % $ 526 M usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
1.4 B - -0.04 % $ 2.62 B usaUSA
Poseida Therapeutics Poseida Therapeutics
PSTX
306 M - - $ 857 M usaUSA
Y-mAbs Therapeutics Y-mAbs Therapeutics
YMAB
216 M - - $ 382 M usaUSA
Satsuma Pharmaceuticals Satsuma Pharmaceuticals
STSA
27.2 M - -0.9 % $ 36.5 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
291 M $ 0.73 -2.01 % $ 62.3 M usaUSA
SpringWorks Therapeutics SpringWorks Therapeutics
SWTX
4.45 B - - $ 3.48 B usaUSA
Metacrine Metacrine
MTCR
13.5 M - - $ 24.2 M usaUSA
Infinity Pharmaceuticals Infinity Pharmaceuticals
INFI
17 M - -46.98 % $ 3.57 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.72 M - - $ 7.46 M israelIsrael
Evelo Biosciences Evelo Biosciences
EVLO
27 M - -14.46 % $ 27.9 M usaUSA
Morphic Holding Morphic Holding
MORF
1.52 B - - $ 2.42 B usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
72.7 M - -15.0 % $ 3.04 M usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
3.11 M - -9.21 % $ 2.55 M usaUSA
Amgen Amgen
AMGN
198 B $ 444.49 -2.93 % $ 239 B usaUSA
IGM Biosciences IGM Biosciences
IGMS
84.7 M - - $ 76.9 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
211 M - - $ 216 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
11.7 M - -33.55 % $ 7.81 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
2.56 B - - $ 3.3 B usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
3.15 M - -37.48 % $ 476 K usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
8.32 M - -9.72 % $ 5.89 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
67.6 M $ 16.51 -4.51 % $ 66.8 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
672 M - 1.02 % $ 90.8 M britainBritain
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
127 M - - $ 154 M usaUSA
Oyster Point Pharma Oyster Point Pharma
OYST
312 M - - $ 300 M usaUSA
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
706 M - - $ 643 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
1.39 B - - $ 2.6 B usaUSA
Lumos Pharma Lumos Pharma
LUMO
24.6 M - - $ 35.3 M usaUSA
MediWound Ltd. MediWound Ltd.
MDWD
131 M $ 13.61 -0.51 % $ 370 M israelIsrael
Syros Pharmaceuticals Syros Pharmaceuticals
SYRS
165 M - -8.44 % $ 3.4 M usaUSA
NanoViricides NanoViricides
NNVC
30.3 M $ 1.19 2.59 % $ 24 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
353 M - -18.25 % $ 5.04 M israelIsrael
GT Biopharma GT Biopharma
GTBP
2.59 M $ 3.44 8.02 % $ 19 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
78.6 M - -74.18 % $ 955 K usaUSA